RxDoctor Payments Data

Snehal Patel, MD

Nephrology · Middletown, OHNPI 1477689792

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 79 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$263
  • Boehringer Ingelheim$227
  • Bayer$224
  • Travere Therapeutics, Inc.$170
  • Calliditas Therapeutics US Inc.$166
  • Amgen$143
  • plus $346 from 7 others

What the payments were for

  • Food & beverage$1,538100%
  • Education$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,541 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$171,690
Medicare patients
460
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol111$87,631
KerendiaFinerenone22$25,379
VeltassaPatiromer Calcium Sorbitex11$20,642
JardianceEmpagliflozin19$15,833
JanuviaSitagliptin Phosphate18$10,981
Sevelamer Carbonate23$4,210
Nifedipine ErNifedipine113$3,576
Torsemide156$3,067
Calcitriol95$1,263
Losartan Potassium138$1,042
Potassium Chloride52$1,025
Calcium Acetate19$842
Pantoprazole Sodium38$619
Hydralazine Hcl55$596
Amlodipine Besylate145$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$263$87,631111 claims
BayerKerendia$224$25,37922 claims
Boehringer IngelheimJardiance$227$15,83319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.

Other nephrology in Middletown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →